PT3728271T - Compostos macrocíclicos para tratar doenças - Google Patents
Compostos macrocíclicos para tratar doençasInfo
- Publication number
- PT3728271T PT3728271T PT188932933T PT18893293T PT3728271T PT 3728271 T PT3728271 T PT 3728271T PT 188932933 T PT188932933 T PT 188932933T PT 18893293 T PT18893293 T PT 18893293T PT 3728271 T PT3728271 T PT 3728271T
- Authority
- PT
- Portugal
- Prior art keywords
- treating disease
- macrocyclic compounds
- macrocyclic
- compounds
- disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607528P | 2017-12-19 | 2017-12-19 | |
| US201862727124P | 2018-09-05 | 2018-09-05 | |
| US201862779283P | 2018-12-13 | 2018-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3728271T true PT3728271T (pt) | 2022-10-06 |
Family
ID=66992951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT188932933T PT3728271T (pt) | 2017-12-19 | 2018-12-18 | Compostos macrocíclicos para tratar doenças |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10745416B2 (pt) |
| EP (2) | EP4151641A1 (pt) |
| JP (2) | JP7194188B2 (pt) |
| KR (1) | KR102814342B1 (pt) |
| CN (1) | CN111511746B (pt) |
| AU (1) | AU2018392332B2 (pt) |
| BR (1) | BR112020012319A2 (pt) |
| CA (1) | CA3083674A1 (pt) |
| CL (1) | CL2020001632A1 (pt) |
| DK (1) | DK3728271T3 (pt) |
| EC (1) | ECSP20033467A (pt) |
| ES (1) | ES2929467T3 (pt) |
| HR (1) | HRP20221502T1 (pt) |
| HU (1) | HUE060711T2 (pt) |
| IL (1) | IL275265B2 (pt) |
| JO (1) | JOP20200152A1 (pt) |
| LT (1) | LT3728271T (pt) |
| MX (1) | MX2020006490A (pt) |
| PE (1) | PE20200937A1 (pt) |
| PH (1) | PH12020550901A1 (pt) |
| PL (1) | PL3728271T3 (pt) |
| PT (1) | PT3728271T (pt) |
| RS (1) | RS63787B1 (pt) |
| SG (1) | SG11202005590PA (pt) |
| SI (1) | SI3728271T1 (pt) |
| SM (1) | SMT202200443T1 (pt) |
| TW (1) | TW201930312A (pt) |
| WO (1) | WO2019126121A1 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI757256B (zh) | 2015-11-02 | 2022-03-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| WO2019079469A1 (en) | 2017-10-18 | 2019-04-25 | Incyte Corporation | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
| JP7194188B2 (ja) | 2017-12-19 | 2022-12-21 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 疾患を治療するための大環状化合物 |
| SG11202005699QA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| JP7422084B2 (ja) | 2018-04-03 | 2024-01-25 | ブループリント メディシンズ コーポレイション | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| EP3833372A4 (en) | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| KR102850357B1 (ko) | 2018-10-22 | 2025-08-27 | 알루미스 인크. | Tyk2 억제제 및 이의 용도 |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| PE20220135A1 (es) | 2019-06-19 | 2022-01-27 | Turning Point Therapeutics Inc | Polimorfos de un inhibidor de cinasas macrociclicas |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| CN114929710B (zh) * | 2019-12-03 | 2024-03-29 | 特普医药公司 | 用于治疗疾病的巨环 |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| US20230219978A1 (en) | 2020-06-04 | 2023-07-13 | Scinnohub Pharmaceutical Co., Ltd | Compound having macrocyclic structure and use thereof |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| US20250002505A1 (en) * | 2021-10-05 | 2025-01-02 | Turning Point Therapeutics, Inc. | Synthesis of macroyclic compounds |
| JP2025524018A (ja) * | 2022-07-22 | 2025-07-25 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式環含有大環状化合物及びその使用 |
| EP4573095A1 (en) * | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| JP7571173B2 (ja) | 2023-02-24 | 2024-10-22 | キヤノン株式会社 | 撮像装置、撮像装置の制御方法、及びプログラム |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021608A1 (en) * | 1993-03-25 | 1994-09-29 | The Upjohn Company | Indoletetralins having dopaminergic activity |
| AU687909B2 (en) | 1993-12-07 | 1998-03-05 | Eli Lilly And Company | Protein kinase C inhibitors |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| ATE301661T1 (de) | 2000-12-08 | 2005-08-15 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
| JP5749645B2 (ja) | 2008-09-08 | 2015-07-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | タンパク質キナーゼ阻害剤としての大環状ピリミジン |
| EP2350075B1 (en) | 2008-09-22 | 2014-03-05 | Array Biopharma, Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| KR101853026B1 (ko) | 2008-10-22 | 2018-04-27 | 어레이 바이오파마 인크. | ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５ａ］ 피리미딘 화합물 |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| CN105693720B (zh) | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012066061A1 (en) * | 2010-11-19 | 2012-05-24 | F. Hoffmann-La Roche Ag | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EP2744507A4 (en) | 2011-08-19 | 2015-01-28 | Merck Sharp & Dohme | CRYSTAL FORMS OF AN HCV PROTEASE HEMMER |
| US9090630B2 (en) | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
| ES2621220T3 (es) | 2012-03-06 | 2017-07-03 | Pfizer Inc. | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas |
| MX381849B (es) | 2012-03-09 | 2025-03-13 | Lexicon Pharmaceuticals Inc | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. |
| EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| CA2954187C (en) * | 2014-07-21 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| ES2979111T3 (es) | 2015-07-06 | 2024-09-24 | Turning Point Therapeutics Inc | Polimorfo de macrociclo de diarilo |
| MX383823B (es) | 2015-07-21 | 2025-03-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales y usos de los mismo. |
| WO2017148325A1 (zh) * | 2016-03-03 | 2017-09-08 | 深圳市塔吉瑞生物医药有限公司 | 一种大环化合物及包含该化合物的组合物 |
| CN106008531B (zh) * | 2016-05-30 | 2019-01-11 | 上海交通大学 | 多环稠合大环内酰胺类化合物的抗胰腺癌用途 |
| CN109715165A (zh) | 2016-07-28 | 2019-05-03 | Tp生物医药公司 | 巨环激酶抑制剂 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| MY201925A (en) | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| WO2019079469A1 (en) | 2017-10-18 | 2019-04-25 | Incyte Corporation | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
| SG11202005699QA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EP3728270A4 (en) * | 2017-12-19 | 2021-06-23 | Turning Point Therapeutics, Inc. | MACROCYCLIC KINASE INHIBITORS AND THEIR USES |
| GB201721235D0 (en) | 2017-12-19 | 2018-01-31 | Syngenta Participations Ag | Polymorphs |
| JP7194188B2 (ja) | 2017-12-19 | 2022-12-21 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 疾患を治療するための大環状化合物 |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| AU2019254979B2 (en) | 2018-04-18 | 2021-08-12 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-12-18 JP JP2020533594A patent/JP7194188B2/ja active Active
- 2018-12-18 PT PT188932933T patent/PT3728271T/pt unknown
- 2018-12-18 ES ES18893293T patent/ES2929467T3/es active Active
- 2018-12-18 EP EP22191652.1A patent/EP4151641A1/en active Pending
- 2018-12-18 PE PE2020000787A patent/PE20200937A1/es unknown
- 2018-12-18 KR KR1020207017739A patent/KR102814342B1/ko active Active
- 2018-12-18 SM SM20220443T patent/SMT202200443T1/it unknown
- 2018-12-18 LT LTEPPCT/US2018/066158T patent/LT3728271T/lt unknown
- 2018-12-18 RS RS20221099A patent/RS63787B1/sr unknown
- 2018-12-18 EP EP18893293.3A patent/EP3728271B1/en active Active
- 2018-12-18 BR BR112020012319-6A patent/BR112020012319A2/pt unknown
- 2018-12-18 WO PCT/US2018/066158 patent/WO2019126121A1/en not_active Ceased
- 2018-12-18 MX MX2020006490A patent/MX2020006490A/es unknown
- 2018-12-18 PL PL18893293.3T patent/PL3728271T3/pl unknown
- 2018-12-18 SG SG11202005590PA patent/SG11202005590PA/en unknown
- 2018-12-18 CN CN201880082563.6A patent/CN111511746B/zh active Active
- 2018-12-18 CA CA3083674A patent/CA3083674A1/en active Pending
- 2018-12-18 JO JOP/2020/0152A patent/JOP20200152A1/ar unknown
- 2018-12-18 SI SI201830779T patent/SI3728271T1/sl unknown
- 2018-12-18 HR HRP20221502TT patent/HRP20221502T1/hr unknown
- 2018-12-18 HU HUE18893293A patent/HUE060711T2/hu unknown
- 2018-12-18 DK DK18893293.3T patent/DK3728271T3/da active
- 2018-12-18 AU AU2018392332A patent/AU2018392332B2/en not_active Ceased
- 2018-12-19 TW TW107145927A patent/TW201930312A/zh unknown
-
2020
- 2020-01-30 US US16/777,717 patent/US10745416B2/en active Active
- 2020-05-05 US US16/866,983 patent/US11286265B2/en active Active
- 2020-06-10 IL IL275265A patent/IL275265B2/en unknown
- 2020-06-15 PH PH12020550901A patent/PH12020550901A1/en unknown
- 2020-06-17 CL CL2020001632A patent/CL2020001632A1/es unknown
- 2020-06-19 EC ECSENADI202033467A patent/ECSP20033467A/es unknown
-
2022
- 2022-02-14 US US17/670,665 patent/US20220306652A1/en not_active Abandoned
- 2022-12-09 JP JP2022197141A patent/JP2023027237A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275265A (en) | Macrocyclic compounds for the treatment of disease | |
| IL248653A0 (en) | Compounds for the treatment of spinal muscular atrophy | |
| IL249229A0 (en) | Compounds for the treatment of brain cancer | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| IL271018A (en) | Compounds for the treatment of triple-negative breast cancer | |
| GB201709402D0 (en) | Compounds for treating t-pll | |
| IL263161B (en) | New compounds for the treatment of parasitic diseases | |
| SI3393468T1 (sl) | Postopki za zdravljenje bolezni imunske pomanjkljivosti | |
| GB201721287D0 (en) | Treatment for inflammatory disease | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| ZA201906047B (en) | Compounds for treating tuberculosis | |
| IL268416A (en) | Pharmaceutical combinations for cancer treatment | |
| PL3601253T3 (pl) | Nowe hamujące ptefb związki makrocykliczne | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| DK3614834T3 (en) | Treatment space for animals | |
| HK40036156A (en) | Macrocyclic compounds for treating disease | |
| HK40070316B (zh) | 用於治疗疾病的杂环化合物 | |
| GB201715210D0 (en) | Macrocyclic compounds | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| GB201704125D0 (en) | Macrocyclic Compounds | |
| GB201704121D0 (en) | Macrocyclic compounds | |
| GB201709404D0 (en) | Compounds for treating TNBC | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201709559D0 (en) | Compounds for treating lupus | |
| GB201712390D0 (en) | Therapeutic compounds |